Hexarelin — compound monograph
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide). Unapproved, research supply. The Institute assesses 2 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Hexarelin
- Compound class
- Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- examorelin · EP-23905 · hexarelin (INN)
- Route as evaluated
- Subcutaneous, intranasal or intravenous in historical studies
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 140703-51-1
- Molecular formula
- C47H58N12O6
- Average mass
- 887.03
- Monoisotopic mass
- 886.46
- ATC classification
- not assigned
§1.3Sequence and structural notes
A hexapeptide secretagogue closely related to GHRP-6, distinguished by 2-methylation of the D-tryptophan at position 2, which increases metabolic stability and potency. It contains two tryptophan residues, making it unusually susceptible to oxidative and photolytic degradation.
§1.4Assessment status
The Institute assesses Hexarelin across 2 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for Hexarelin, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | Marked acute growth-hormone release; the response attenuates substantially over 8 to 16 weeks of continuous administration | Low | 2 |
| Atherosclerotic cardiovascular disease and cardiovascular risk reduction | No randomised human evidence identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.